tbuckley/cabot-search huggingface dataset:
THE CREMASTERIC REFLEX IN SCIATICA.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Affiliation
Authors: Katharine Harding, Emma Tallantyre, Neil Robertson
Journal: JAMA Neurology (2019)

those patients with the most active disease compared with treated cohorts in other western countries.However, alemtuzumab has been available in our center off-license since 2005, and our study's long-term outcomes 4 mirror those reported in another alemtuzumab-treated cohort. 5 The expansion in DMTs in the last decade has led to the development of several options to treat relapsing MS but a lack of data or consensus on DMT sequencing choices.We agree with the authors that RCT data are urgently needed 6 and, anticipating this, used the results from this observational study as preliminary data to inform the development of the Determining the Effectiveness of Early Intensive vs Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) trial.DELIVER-MS is a pragmatic parallel group, randomized clinical trial designed to compare outcomes of people treated with an early intensive approach vs an escalation approach.In 24 centers (12 in the United States and 12 in the United Kingdom), we aim to recruit 400 randomized and 400 observational patients with a definite diagnosis of MS, onset in the last 5 years, who are treatment naive, to receive either an escalation approach or an early intensive treatment approach.The primary end point is brain volume loss at 36 months and secondary end points include the accumulation of disability and health-related quality of life.We look forward to the results of this trial and hope that it will provide a more definitive answer to the question of the effect of initial treatment approaches on long-term outcomes in MS.
Prognostic significance of the S‐phase fraction of light‐chain‐restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486
Authors: M.C. Trendle, T. Leong, R.A. Kyle, J.A. Katzmann, M.M. Oken, N.E. Kay, B.G. Van Ness, P.R. Greipp
Journal: American Journal of Hematology (1999)

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the proliferative activity (% S-phase) as determined by two-color flow cytometry for cytoplasmic immunoglobulin (cIg) light chain and DNA content also had prognostic significance. As part of Eastern Cooperative Oncology Group clinical trial E9486, 500 patients had successful performance of the bone marrow PCLI. Of 349 patients who had flow cIg and DNA content cytometry, 210 had adequate data to reliably calculate S-phase %. Patients with low % S-phase fraction (<2%) had a significant overall survival advantage over patients high % S-phase fraction (≥2%), median survivals 4.1 vs. 2.9 years (P = 0.032). Measurement of the S-phase % by flow cytometry gives significant prognostic information in patients with newly diagnosed myeloma. However, in multivariate analysis, S-phase % did not add prognostic information when PCLI was in the model. S-phase % added prognostic information only when all cases with flow measurement of S-phase % were included, and when PCLI was excluded from the model. Discriminating a population of only cIg positive cells proved difficult in patients with a low percentage of bone marrow plasma cells. Methodology to measure S-phase % in patients with a low percent plasma cells is needed before this technique can be used for diagnosis and prognosis in myeloma. Am. J. Hematol. 61:232–237, 1999. © 1999 Wiley-Liss, Inc.
Addiction medicine
Authors: J. E. Franklin
Journal: JAMA (1993)

The health care debates of 1993 highlight the need for better knowledge of service utilization patterns, treatment effectiveness, and cost-effectiveness of health care. Addiction medicine will be increasingly challenged to provide highquality, cost-effective treatments to maximize the effectiveness of health care expenditures in this area. Updated 1-year prevalence data from the Epidemiologic Catchment Area Program report that specialists in mental and addictive disorders provide treatment for 5.9% of the US population, and only 28.5% of people with mental or addictive disorders seek treatment.<sup>1</sup>Over 30 million persons are uninsured in this country. A significant percentage of alcohol and drug abusers fall into this category. The extent to which addiction treatment services would be available in a climate of managed competition is unclear and concerning. Few studies specifically address cost-effectiveness of treatment. Goodman et al,<sup>2</sup>in an analysis of short-term treatment costs, highlighted the complexity of cost analysis research
THE RE-ASSEMBLING OF SCHOOLS.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Delta-hepatitis--Massachusetts
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Levamisole Toxicity
Authors: Leonard DeLorenzo, James A. Stewart
Journal: Journal of Clinical Oncology (1990)

To the Editor: Levamisole use will no doubt increase following the recent report by Laurie et al and the National Cancer Institute (NCI) Clinical Alert both related to the use of levamisole/fluorouracil (5-FU) as adjuvant treatment for colon cancer. Toxicity of levamisole is generally described as mild with nausea, diarrhea, and leukopenia being the most significant adverse effects with fatigue, dermatitis, and stomatitis also seen. Depsite the generally mild nature of the toxicity, occasional patients experience enough side effects to cause discontinuation of therapy. We report a patient with an unusual levamisole toxicity that resulted in discontinuation of the drug. A 47-year-old woman with node-positive colon cancer agreed to randomization in a clinical trial (EST 2284, Intergroup-0035) evaluating levamisole versus levamisole with 5-FU. She received levamisole 50 mg orally three times a day every 2 weeks and 5-FU 450 mg/m 2 weekly. In the fifth month of treatment, she experienced the onset of bilateral arm pain occurring late in the first day of levamisole and resolving by 24 hours after the last dose. These symptoms also occurred with the next course of levamisole. Clinical examination showed upper arm pain with aching and stiffness in the wrists and fingers. Forearm muscles were tender, but there was no joint inflammation. There was no fever, rash, mucositis, leukopenia, or eosinophilia. The erythrocyte sedimentation rate was 8 mm/hr, creatine kinase 31 U/L, and antinuclear antibodies less than 1:20. The next course of levamisole resulted in similar but more severe pain with significant disruption of the patient's work as a florist. 5-FU alone was continued with no recurrence of these symptoms. Three years later the patient is well without pain or evidence for recurrent tumor. This symptom complex is clearly related to the levamisole treatment and might be considered a variant of the "flu-like" symptoms reported in other levamisole trials. We suggest that clinicians using levamisole in randomized trials or without the NCI Group C mechanism be aware of the wide spectrum of toxicities that may be seen with this interesting drug for the purpose of pretreatment discussion with patients and for the monitoring of therapy. The last sentence of the letter-to-the-editor entitled "Levamisole Toxicity" by Drs Leonard DeLorenza and James A. Stewart, published in the February 1990 issue (J Clin Oncol 8:365, 1990) contained an error. The sentence should have read: "We suggest that clinicians using levamisole in randomized trials or within the NCI Group C mechanism be aware of the wide spectrum of toxicities that may be seen with this interesting drug for the purpose of pretreatment discussion with patients and for the monitoring of therapy."
Appendix
Journal: Circulation (2005)

Previous "Giants" HonoreesThe American Heart Association began the tradition of honoring "giants" in resuscitation science at the 1985 conference establishing new resuscitation guidelines.ILCOR joined this tradition in 2000."Giants" honorees are selected based on ongoing landmark contributions to cardiopulmonary resuscitation and emergency cardiovascular care in general; authorship of books, articles, and education and teaching materials in the field of emergency cardiovascular care; national and international recognition for their contributions to the field; and development of innovative technological and scientific breakthroughs.
Leukemia monitoring with fungal bone marrow cultures
Authors: W. T. Hughes
Journal: JAMA (1971)

<i>In an approach to detect mycotic infection early in leukemic patients 322 bone marrow specimens were collected from 187 children with leukemia for fungal cultures concomitantly with specimens for routine hematological examination. Fungi were isolated from seven patients</i>. Histoplasma capsulatum<i>was found in three</i>, Cryptococcus neoformans<i>in two, and</i>Candida albicans<i>in two of the patients. Six of the children were proven to have early systemic infection from these fungi and were successfully treated.</i>
From the Institute of Medicine
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Henri Hallopeau (1842-1919)
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats</i>: Average Age at Death*<sup>,</sup>† by Race/Hispanic Origin and Sex — National Vital Statistics System, United States, 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Male FemaleSex Average age at death (yrs) White, non-Hispanic Asian or Paci c Islander, non-Hispanic Hispanic Black, non-Hispanic * The average age at death is the sum of age at death for all deaths from each group divided by the total number of deaths from that group.† Records with age not stated were not included.In 2017, in the United States, the average age at death among males was highest for non-Hispanic whites (72.0 years), followed by non-Hispanic Asians or Pacific Islanders (70.0), Hispanics (62.2), and non-Hispanic blacks (62.1).Among females, the average age at death was highest for non-Hispanic whites (78.1 years), followed by non-Hispanic Asians or Pacific Islanders (75.8),Hispanics (70.7), and non-Hispanic blacks (69.7).
Molecular Medicine
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 854: Combination effect of low dose Cytarabine and pan-RAF inhibitor LY3009120 in AML cells with RAS mutations
Authors: Jihyun PARK, Sung-Soo Yoon, Youngil Koh
Journal: Cancer Research (2019)

Abstract The alterations of RAS oncogenes were known to be involved in various cancers. In acute myeloid leukemia (AML), there are 6% of alterations in KRAS and 13% in NRAS. The RAS/RAF/MEK/ERK cascade has roles in promoting hematopoietic cell growth, inhibiting apoptosis, and is related to chemotherapy resistance. Fortunately, the recent advance in pharmacology suggests the advent of potentially efficacious RAS inhibitors. However, current RAS inhibitor development is focused on solid tumors. We, therefore, tried to identify if potential RAS targeting molecule would be effective in hematologic malignancies. Here we focused on the combination of LY3009120, a pan-RAF inhibitor that targets RAF with widely used antimetabolite agent cytarabine on AML cell line. We used AML cell lines, HL-60, NB-4 which have NRAS/KRAS mutation and KG-1 as RAS wild-type control cell line. In the cytotoxicity test, we first performed a single effect of cytarabine and LY3009120 in the AML cell lines using cytotoxicity assay. Based on the single treat experiment, cytarabine and LY3009120 were simultaneously treated on three AML cell lines at the indicated concentration. Above all, there was a strong synergistic effect on combination treat of cytarabine containing LY3009120 in HL-60 (56.8%, p=0.0001) and NB-4 (66%, p&amp;lt;0.0001) compared with KG-1 cell line (8%). In order to examine the changes in RAF/MAPK pathways, we demonstrated western blotting using antibodies to RAS, RAF, MAPK signaling molecules. In HL-60, the phosphorylation of MEK was slightly increased by the single treat of cytarabine or LY3009120. However, the combination treatment of cytarabine and LY3009120 decreased the phosphorylation of MEK. And more, in NB-4, the phosphorylation of ERK (T202/Y204) was not affected by single treatment while the combination treatment decreased ERK phosphorylation at low concentration of LY3009120. Furthermore, we investigated the underlying mechanisms of the combined effect, PARP protein cleavage indicating cell death was examined. PARP cleavage was observed in HL-60 and NB-4 after treatment, whereas KG-1 did not show any change in PARP after treatment. In conclusion, we show the synergistic effect between cytarabine and LY3009120 on AML cell lines which have the mutation on RAS gene. Even at the low concentration of cytarabine, combining LY3009120 significantly increases the anti-cancer effect. With our data, we suggest that novel therapeutic strategies for AML patients with RAS mutation. Citation Format: Jihyun PARK, Sung-Soo Yoon, Youngil Koh. Combination effect of low dose Cytarabine and pan-RAF inhibitor LY3009120 in AML cells with RAS mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 854.
The Process of Compensation and some of its Bearings on Prognosis and Treatment
Authors: B. Bramwell
Journal: BMJ (1888)

mitral.Any poet-mortem clots which may be adhering to the edge of the valve are removed with care, so as not to disturb the position of the cusps.An aperture sufficiently large to admit the brass nozzle is next made into the apex of the left ventricle in the line of incision which will afterwards be required to lay the ventricle open.The nozzle is then introduced, and air driven in by the bellows in the manner before described.The heart should meanwhile be suspended by the cut edges of the auricle.A series of hooks fixed on supports is useful for this purpose, the supports being movable 80 as to allow of the proper apposition of the Cusps.Thie slightest incompetency can be detected quite as much by the irregular manner in whicai the cusps mutually adjust them- selves, as by the escape of air between them.The same means of demonstration is to be followed in the case of the tricuspid, and, after its condition has been ascertained, the incision in the left ventricle is carried lip as close as possible to the root of the aorta, without, of course, injuring the aortic ring.The heart is now suspended, as before, by the cut edges of the ventricle, and the nozzle is tied into the distal end of the aorta.The aorta should either be cut off at the termination of the ascending part of the arch, or be laid open up to this point.The nozzle both in the case of the mitral and in that of the aortic may be simply held in with the hand, or it may be tied in; or, what is even preferable, a simple clamp apparatus may be attached to its ex- tremity, which seizes the cut edge of the vessel or cavity into which the nozzle is introduced, and holds it air-tight or nearly so.In watching the action of the valve, the ventricular aspect should be turned upwards, the air being driven in from below.The pulmonary artery orifice is next tested in the same manner.In a perfectly healthy heart it will be found that the sortie, mitral, and pulmonary artery valves are quite competent, but, so far as my present experience goes, I have never met with a tri- cuspid in man which will stand the test.There is always a slight leakage, even when the cusps are perfectly free to move.